Tag: ADCT-301
Enrollment Completed for Pivotal Phase II Clinical Trial of Camidanlumab Tesirine...
Enrolment for the pivotal Phase II clinical trial (NCT04052997) evaluating the efficacy and safety of camidanlumab tesirine (formerly ADCT-301) in patients with relapsed or...
Preclinical Study Supports Continued Evaluation of CD25-targeted ADC in Selected Advanced...
Preclinical data for camidanlumab tesirine (formerly ADCT-301; ADC Therapeutics), published in the Journal for ImmunoTherapy of Cancer, the online journal of the Society for...
ADC Therapeutics On Track to File BLA for Loncastuximab Tesirine for...
This week Swiss-based ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for patients with hematological malignancies and...
FDA Lifts Partial Clinical Hold on Pivotal Phase II Clinical Trial...
Earlier this week the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold on the pivotal Phase II clinical study of camidanlumab...
15th ICML: Camidanlumab Tesirine Shows High Overall Response Rate in R/R...
During the International Conference on Malignant Lymphoma (ICML), one of the must-attend events for the scientific community involved in the study and treatment of...
Pyrrolobenzodiazepine-based ADCs Demonstrate Potential in R/R Lymphomas
The International Conference on Malignant Lymphoma (ICML) has, since its first edition in 1981, become one of the must-attend conferences for the scientific community...
First Patient Dosed in Phase Ib Clinical Trial of Camidanlumab Tesirine...
A first patient has been dosed in Phase Ib clinical trial of camidanlumab tesirine, also know ADCT-301, a proprietary antibody-drug conjugate or ADC being...
Interim Phase I Data from Camidanlumab Tesirine (ADCT-301) Shows Encouraging Preliminary...
Clinical data from two ongoing Phase I clinical trials evaluating camidanlumab tesirine, also known as ADCT-301* or "Cami-T", in important subtypes of lymphoma and...
Interim Data Shows Favorable Tolerability and Efficacy Results of ADCT-301 in...
Interim results from an ongoing Phase I, open label, dose-escalating study evaluating ADCT-301, being developed by ADC Therapeutics for the treatment of relapsed or refractory...
Successful Funding Round Expected to Accelerate ADC Therapeutics’ Clinical Development
Swiss Biotech company ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates or ADCs for the treatment...
